


-2-


AMENDMENTS TO THE CLAIMS

1. (original) A compound having the structural formula



or a pharmaceutically acceptable salt thereof, wherein

R is




R^1 , R^2 , R^3 , R^4 and R^5 are independently selected from the group consisting of H, alkyl and alkoxyalkyl;

R^6 is H, alkyl, hydroxyalkyl or $-\text{CH}_2\text{F}$;

R^7 , R^8 and R^9 are independently selected from the group consisting of H, alkyl, alkoxy, alkylthio, alkoxyalkyl, halo and $-\text{CF}_3$;

Z is R^{10} -aryl, R^{10} -heteroaryl or



R^{10} is 1 to 5 substituents independently selected from the group consisting of hydrogen, alkyl, alkenyl, hydroxy, alkoxy, hydroxyalkyl, hydroxy-alkoxy, alkoxyalkyl, alkoxyalkoxy, alkoxy-alkoxy-alkyl-, (di-alkoxy)-alkyl, (hydroxy)-alkoxyalkyl, R^{15} -cycloalkyl, R^{15} -cycloalkylalkyl, cycloalkyl-oxy, cycloalkyl-O-alkoxy, alkyl- SO_2 -, alkyl- SO -, halo, -CN, cyanoalkyl, $-\text{CHF}_2$, $-\text{CF}_3$, $-\text{OCHF}_2$, $-\text{OCF}_3$, $-\text{C}(\text{O})\text{R}^{13}$, $-\text{O-alkylene-C}(\text{O})\text{OR}^{13}$, $-\text{C}(\text{O})\text{O-alkyl}$, $-\text{N}(\text{R}^{11})(\text{R}^{12})$, $\text{N}(\text{R}^{11})(\text{R}^{12})$ -alkyl, $\text{N}(\text{R}^{11})(\text{R}^{12})$ -alkoxy, $-\text{C}(\text{O})\text{N}(\text{R}^{13})(\text{R}^{16})$, R^{11} -heteroaryl, R^{15} -heterocycloalkyl, R^{15} -heterocycloalkyl-alkyl, R^{15} -heterocycloalkyl-alkoxy, R^{15} -heterocycloalkyl-oxy, CF_3 -alkylene-O-alkyl, CF_3 -hydroxyalkyl, (CF_3) (hydroxy)alkoxy, cyano-alkoxy, -alkylene-C(O)-O-alkyl,

-3-

-SO₂-N(alkyl)₂, (cycloalkyl)hydroxyalkyl, (hydroxyalkyl)alkoxy, (dihydroxy)alkyl, (dihydroxy)alkoxy, -C(=NOR¹⁷)-alkyl and -C(=NOR¹⁷)-CF₃;

or two R¹⁰ groups on adjacent carbon ring atoms together form -O-CH₂-O-, -O-(CH₂)₂-O-, -CH₂-O-(CH₂)₂-O-, -O-(CH₂)₂-, -(CH₂)₃-O-, -O-(CH₂)₃-O-, -(CH₂)₃-, wherein the ring formed by the two R¹⁰ substituents and the ring carbon atoms to which they are attached is substituted by R¹⁶;

or two R¹⁰ groups on adjacent carbon ring atoms together form -N(R¹¹)-C(O)-O-, -N(R¹¹)-C(O)-S-, -(CH₂)₂CH(OR¹⁸)-, -CH₂CH(OR¹⁸)CH₂-, -(CH₂)₃CH(OR¹⁸)-, -(CH₂)₂CH(OR¹⁸)CH₂-, -(CH₂)₂C(O)-, -CH₂C(O)CH₂-, -(CH₂)₃C(O)-, -(CH₂)₂C(O)CH₂-, -O(CH₂)₂CH(OR¹⁸)- or -OCH₂CH(OR¹⁸)CH₂-, wherein the ring formed by two R¹⁰ substituents and the ring carbon atoms to which they are attached is optionally substituted on a carbon atom by hydroxyalkyl or alkoxyalkyl;

each R¹¹ is independently selected from the group consisting of H and alkyl;

each R¹² is independently selected from the group consisting of H, alkyl, hydroxyalkyl, alkoxyalkyl, -C(O)-alkyl, -C(O)O-alkyl, (alkoxy)hydroxyalkyl, alkoxyalkyl-C(O)-, -SO₂alkyl, -alkylene-C(O)alkyl and -alkylene-C(O)O-alkyl;

R¹³ is H, alkyl or -CF₃;

R¹⁴ is H, alkyl, alkoxyalkyl, alkyl-C(O)- or alkoxy-C(O)-;

R¹⁵ is 1 to 3 substituents independently selected from the group consisting of H, alkyl, -OH, alkoxy, alkoxyalkyl and hydroxyalkyl; or two R¹⁵ substituents, taken together with the carbon to which they are both attached, form a -C(=O)- group;

R¹⁶ is H, alkyl, alkoxyalkyl, OH or hydroxyalkyl;

R¹⁷ is H or alkyl; and

R¹⁸ is H or alkyl.

2. (original) A compound of claim 1 wherein R is -C≡CR⁶.
3. (original) A compound of claim 2 wherein R⁶ is H or alkyl.
4. (original) A compound of claim 1 wherein R², R³, R⁴ and R⁵ are each H.
5. (original) A compound of claim 1 wherein Z is R¹⁰-aryl or R¹⁰-heteroaryl.


-4-

6. (original) A compound of claim 5 wherein Z is R¹⁰-phenyl.
7. (original) A compound of claim 6 wherein R¹⁰ is 1, 2 or 3 substituents independently selected from the group consisting of H, halo, -C(O)R¹³, alkyl, alkoxy, hydroxyalkyl, (cycloalkyl)hydroxyalkyl, hydroxyalkoxy, alkoxyalkoxy, alkoxyalkyl, and cyanoalkyl.
8. (original) A compound of claim 7 comprising two R¹⁰ substituents wherein one R¹⁰ is halo and the other R¹⁰ is halo, -C(O)R¹³, alkyl, alkoxy, hydroxyalkyl, (cycloalkyl)hydroxyalkyl, hydroxyalkoxy, alkoxyalkoxy, alkoxyalkyl or cyanoalkyl.
9. (original) A compound of claim 8 comprising two R¹⁰ substituents wherein one R¹⁰ is o-fluoro and the other R¹⁰ is halo, -C(O)R¹³, alkyl, alkoxy, hydroxyalkyl, (cycloalkyl)hydroxyalkyl, hydroxyalkoxy, alkoxyalkoxy, alkoxyalkyl or cyanoalkyl.
10. (original) A compound of claim 5 wherein Z is R¹⁰-heteroaryl.
11. (original) A compound of claim 10 wherein Z is R¹⁰-benzoxazolyl or R¹⁰-benzisoxazolyl and R¹⁰ is 1 or 2 substituents independently selected from the group consisting of H, halo and alkyl.
12. (original) A compound of claim 11 wherein one R¹⁰ is fluoro and one R¹⁰ is methyl.
13. (original) A compound of claim 1 wherein R is -C≡CR⁶, R², R³, R⁴ and R⁵ are each H, and Z is R¹⁰-aryl or R¹⁰-heteroaryl.
14. (original) A compound of claim 13 wherein Z is R¹⁰-phenyl and R¹⁰ is two substituents wherein one R¹⁰ is halo and the other R¹⁰ is halo, -C(O)R¹³, alkyl, alkoxy, hydroxyalkyl, (cycloalkyl)hydroxyalkyl, hydroxyalkoxy, alkoxyalkoxy, alkoxyalkyl or cyanoalkyl.

-5-

15. (original) A compound of claim 13 wherein Z is R¹⁰-benzoxazolyl or R¹⁰-benzisoaxazolyl and R¹⁰ is 1 or 2 substituents independently selected from the group consisting of H, halo and alkyl.

16. (original) A compound of claim 1 selected from the group consisting of



-6-

17. (original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 in a pharmaceutically acceptable carrier.
18. (currently amended) A method of treating Parkinson's disease or depression ~~central nervous system diseases or stroke~~, comprising administering an effective amount of a compound of formula I to a mammal in need of such treatment.
19. (canceled)
20. (canceled)
21. (original) A pharmaceutical composition comprising a therapeutically effective amount of a combination of a compound of claim 1, and 1 to 3 other agents useful in treating Parkinson's disease in a pharmaceutically acceptable carrier.
22. (original) A method of treating Parkinson's disease comprising administering to a mammal in need of such treatment an effective amount of a combination of a compound of claim 1, and 1 to 3 other agents useful in treating Parkinson's disease.
23. (original) The method of claim 22 wherein the other agents are selected from the group consisting of L-DOPA, dopaminergic agonists, MAO-B inhibitors, DOPA decarboxylase inhibitors and COMT inhibitors.